Identifying optimal first-line interventions for advanced non-small cell lung carcinoma according to PD-L1 expression: a systematic review and network meta-analysis

References

• Huang Q, Hua Z, Hai J, Socinski MA, Lim E, Chen H, Stebbing J. Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials. Oncoimmunology 2018;2017(12):e1396403.
   Web of Science ®Google Scholar
• Shuai W, Hao J, Hao W, Yong F, Tan L. Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer. J. Oncoimmunology, 2018;7(8):e1457600. doi:10.1080/2162402X.2018.1457600.
   Google Scholar
• Reck M, Rodríguezabreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823. doi:10.1056/NEJMoa1606774.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Chen C, Zhang X, Fu S, Xue C, Ma Y, Fang W, Yang Y, Hou X, Huang Y. Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis. J ImmunoTher Cancer. 2018;6. doi:10.1186/s40425-018-0477-9.
   Web of Science ®Google Scholar
• Low JL, Walsh RJ, Ang Y, Chan G, Soo RA. The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer. Ther Adv Med Oncol. 2019;11:175883591987036. doi:10.1177/1758835919870360.
   Web of Science ®Google Scholar
• Zhang H, Liu N, Gao S, et al. Can an ¹⁸F-ALF-NOTA-PRGD2 PET/CT Scan Predict Treatment Sensitivity to Concurrent Chemoradiotherapy in Patients with Newly Diagnosed Glioblastoma? Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2016;57(4):524-529. doi:10.2967/jnumed.115.165514
   Google Scholar
• Rossi A. New options for combination therapy for advanced non-squamous NSCLC. Expert Rev Respir Med. 2019;13(11):1095–12. doi:10.1080/17476348.2019.1667233.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savović J, Schulz KF, Weeks L, Sterne JAC. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ Br Med J. 2011;343:889–893. doi:10.1136/bmj.d5928.
   Web of Science ®Google Scholar
• Gadgeel SM, Stevenson JP, Langer CJ, Leena G, Hossein B, Amita P, Villaruz LC, Matthew G, Ralph H, Chih-Hsin YJ. Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: phase 1 cohorts from the KEYNOTE-021 study. J. Lung cancer 2018;125:273–281. doi:10.1016/j.lungcan.2018.08.019
   Google Scholar
• Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078–2092. doi:10.1056/NEJMoa1801005.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Rodríguezabreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. Lancet Oncol. 2017;18:1600–1609. doi:10.1016/S1470-2045(17)30690-3.
   PubMed Web of Science ®Google Scholar
• Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G, Srimuninnimit V, Laktionov KK, Bondarenko I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819–1830. doi:10.1016/S0140-6736(18)32409-7.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379:2040–2051. doi:10.1056/NEJMoa1810865.
   PubMed Web of Science ®Google Scholar
• West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp HG, Daniel D, McCune S, Mekhail T, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:924–937. doi:10.1016/S1470-2045(19)30167-6.
   PubMed Web of Science ®Google Scholar
• Socinski MA, `Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodrã-Guez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:NEJMoa1716948. doi:10.1056/NEJMoa1716948.
   Web of Science ®Google Scholar
• Reck M, Mok TSK, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019;7:387–401. doi:10.1016/S2213-2600(19)30084-0.
   PubMed Web of Science ®Google Scholar
• Jotte RM, Cappuzzo F, Vynnychenko I, Stroyakovskiy D, Abreu DR, Hussein MA, Soo RA, Conter HJ, Kozuki T, Silva C, et al. IMpower131: primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. J Clin Oncol. 2018;36(18_suppl):LBA9000LBA9000. doi:10.1200/JCO.2018.36.18_suppl.LBA9000.
   Web of Science ®Google Scholar
• Papadimitrakopoulou V, Cobo M, Bordoni R, Dubray-Longeras P, Szalai Z, Ursol G, Novello S, Orlandi F, Ball S, Goldschmidt J, et al. IMpower132: PFS and safety results with 1L atezolizumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. J Thoracic Oncol. 2018;13:S332S333. doi:10.1016/j.jtho.2018.08.262.
   Web of Science ®Google Scholar
• Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17:14971508.
   Web of Science ®Google Scholar
• Reck DR-AM, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O’Brien M, et al., KEYNOTE-024 3-year survival update: pembrolizumab VS platinum-based chemotherapy for advanced non-small non-small-cell lung cancer.. 2019 World Conference on Lung Cancer Abstract Book. [accessed 2019 Sep 8. https://wclc2019.iaslc.org/onsite-information/.
   Google Scholar
• Jotte FCR, Vynnychenko I, Stroyakovskiy D, Abreu DR, Hussein M, Soo R, Conter H, Kozuki T, Huang K, Graupner V, et al., IMpower131: final os results of Carboplatin + Nab-Paclitaxel ± Atezolizumab in advanced Squamous NSCLC. 2019 World Conference on Lung Cancer Abstract Book. [accessed 2019 Sep 8]. https://wclc2019.iaslc.org/onsite-information/.
   Google Scholar
• Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodriguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288–2301. doi:10.1056/NEJMoa1716948.
   PubMed Web of Science ®Google Scholar
• Wu -LZY-L, Fan Y, Zhou J, Zhang L, Zhou Q, Li W, Hu C, Chen G, Zhang X, Zhou C, et al., KEYNOTE-042 China Study: first-line pembrolizumab VS chemotherapy in Chinese patients with advanced NSCLC with PD-L1 TPS≥1%. 2019 World Conference on Lung Cancer Abstract Book. [accessed 2019 Sep 8]. https://wclc2019.iaslc.org/onsite-information/.
   Google Scholar
• Zhou GCC, Huang Y, Zhou J, Lin L, Feng J, Wang Z, Shu Y, Shi J, Hu Y, Wang Q, et al., A randomized phase 3 study of camrelizumab plus chemotherapy as 1st line therapy for advanced/metastatic nonsquamous non-small cell lung cancer. 2019 World Conference on Lung Cancer Abstract Book. [accessed 2019 Sep 8]. https://wclc2019.iaslc.org/onsite-information/.
   Google Scholar
• Peters SRS, Paz-Ares L, Caro RB, Zurawski B, Kim S-W, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, et al., Nivolumab+low-dose ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: checkmate 227 part 1 final analysis. (2019 European Society for Medical Oncology (ESMO)).
   Google Scholar
• David FDM, Spigel R, Giaccone G, Reinmuth N, Vergnenegre A, Barrios CH, Morise M, Felip E, Andric Z, Geater S, et al., IMpower 110: interimOS analysis of a phase III study of atezolizumab vs platinum-based chemotherapy as 1L treatment in PD-L1-selected NSCLC. 2019ESMO congress.
   Google Scholar
• Zhou Y, Lin Z, Zhang X, Chen C, Zhao H, Hong S, Zhang L. First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy. J ImmunoTher Cancer. 2019;7. doi:10.1186/s40425-019-0600-6.
   Web of Science ®Google Scholar
• Zhoum H, Zhang Y, Chen G, Zhao S, Liu J, Hong S, Zhang L. Which is the optimal immunotherapy for advanced non-squamous non-small-cell lung cancer in combination with chemotherapy? J Thoracic Oncol. 2018;13:S1059–S1060. doi:10.1016/j.jtho.2018.10.049.
   Web of Science ®Google Scholar
• Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity. 2013;39:74–88. doi:10.1016/j.immuni.2013.06.014.
   PubMed Web of Science ®Google Scholar
• Govindan R, Szczesna A, Ahn MJ, Schneider CP, Mella PFG, Barlesi F, Han B, Ganea DE, Pawel JV, Vladimirov V, et al. Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non–small-cell lung cancer. J Clin Oncol. 2017;35:3449–3457. doi:10.1200/JCO.2016.71.7629.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salman P, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378:2093–2104. doi:10.1056/NEJMoa1801946.
   PubMed Web of Science ®Google Scholar
• Peters S, Antonia S, Goldberg SB, Heymach JV, Kim ES, Nakagawa K, Papadimitrakopoulou V, Mukhopadhyay P, McIntosh S, Rizvi NA. MYSTIC: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC. J Thoracic Oncol. 2016;11:S139–S140. doi:10.1016/S1556-0864(16)30300-8.
   PubMed Web of Science ®Google Scholar
• Hegde PS, Wallin JJ. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. J. Seminars in cancer biology 2018;52(2):117–124. doi:10.1016/j.semcancer.2017.12.002
   Google Scholar
• Chen DS, Hurwitz H. Combinations of bevacizumab with cancer immunotherapy. Cancer J (United States). 2018;24:193–204.
   Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):123–135. doi:10.1056/NEJMoa1507643.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim D-W, Felip E, Pérez-Gracia JL, Han J-Y, Molina J, Kim J-H, Arvis CD, Ahn M-J. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–1550. doi:10.1016/S0140-6736(15)01281-7.
   PubMed Web of Science ®Google Scholar
• Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837–1846. doi:10.1016/S0140-6736(16)00587-0.
   PubMed Web of Science ®Google Scholar
• Roach C, Zhang N, Corigliano E, Jansson M, Toland G, Ponto G, Dolled-Filhart M, Emancipator K, Stanforth D, Kulangara K. Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non–small-cell lung cancer. Appl Immunohistochem Mol Morphol. 2016;24(6):392–397. doi:10.1097/PAI.0000000000000408.
   PubMedGoogle Scholar
• Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):NEJMoa1716948. doi:10.1056/NEJMoa1716948.
   Web of Science ®Google Scholar
• Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, Feng J, He J, Han B, Wang J. BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol Off J Am Soci Clin Oncol. 2015;33:2197.
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P,R, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: aVAil. J Clin Oncol Off J Am Soci Clin Oncol. 2009;27(8):1227. doi:10.1200/JCO.2007.14.5466.
   PubMed Web of Science ®Google Scholar